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Atrial fibrillation (AF) is the most prevalent arrhythmia treated in emergency departments (EDs),1–3 and the most 
serious complication is stroke or systemic embolism.4 The 
high effectiveness of oral anticoagulants in preventing these 
complications5 has produced general agreement that stroke 
prophylaxis is the mainstay of AF management in all health-
care settings.6–8
Given the number of these patients attended in EDs who are 
at high risk of stroke but not receiving anticoagulants,3,9,10 the 
ED may be an underused resource for starting anticoagulation, 
although this remains controversial. Some authors have pos-
tulated that ED physicians should only inform patients about 
the need for stroke prophylaxis, and oral anticoagulation 
should be prescribed in other settings.11 On the other hand, 
as substantial underuse has been reported in them,12,13 numer-
ous authors have called for coordinated efforts, including ED 
involvement, to improve treatment.14
No study to date has prospectively addressed the long-
term outcomes of ED prescription and its contribution to 
stroke prophylaxis. Analysis of the feasibility, benefits, and 
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-VASc score. At ED discharge, 935 
patients (80.5%) were receiving anticoagulant therapy, de novo in 237 patients (55.2% of 429 not previously treated). At 
1 year, 48 (4.1%) patients presented major bleeding events, and 151 (12.9%) had died. Anticoagulation first prescribed in 
the ED was not related to major bleeding (hazard ratio, 0.976; 95% confidence interval, 0.294–3.236) and was associated 
with a decrease in mortality (hazard ratio, 0.398; 95% confidence interval, 0.231–0.686). Adjusting by the main clinical 
and sociodemographic characteristics, concomitant antiplatelet treatment, or destination (discharge or admission) did not 
affect the results.
Conclusions—Prescription of anticoagulation in the ED does not increase bleeding risk in atrial fibrillation patients at high risk 
of stroke and contributes to decreased mortality.   (Stroke. 2017;48:1344-1352. DOI: 10.1161/STROKEAHA.116.014855.)
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long-term safety of ED prescription of anticoagulants could 
contribute to categorical recommendations for stroke prophy-
laxis in this setting.
The objectives of the EMERG-AF study (Emergency 
Department Stroke Prophylaxis and Guidelines Implementation 
in Atrial Fibrillation) were to analyze thromboprophylaxis pre-
scription in patients with AF attended in the ED and long-term 
outcomes: major bleeding, stroke or systemic embolism, and 
death.
Methods
Study Design and Setting
The EMERG-AF was a prospective, multicenter, observational cohort 
study performed in 62 Spanish EDs from April 2013 to June 2014. 
Data were collected prospectively at the first ED visit (April 1–30, 
2013) on study inclusion and at a 1-year (±4 weeks) follow-up visit.
To guarantee a hospital sample representative of the Spanish 
healthcare system, study centers were selected from the national 
catalogue published by Spain’s Ministry of Health and Social Policy. 
Centers were categorized by size, level of services, and location; the 
scientific committee recruited 25% of the eligible centers, weighted 
by category, to participate. The study was approved by the Scientific 
Ethics Committee of each participating hospital.
Selection of Participants
We included consecutive patients older than 18 years attended in the 
ED for any reason during the study period with AF documented in 
clinical records or demonstrated in an ECG obtained when the treat-
ing ED physician considered it necessary during clinical evaluation. 
Exclusion criteria were atrial flutter and clinical trial participation.
A total of 1138 patients were considered necessary for a represen-
tative sample, assuming an estimated anticoagulation ratio of 60%, 
2-sided 95% confidence interval (CI), ±3% sensitivity and 10% losses 
to follow-up.
Informed consent was obtained in all cases. To guarantee confi-
dentiality, access to patient identity was restricted to the treating ED 
physician. The central database contained identification numbers for 
individual study participants and was password protected.
Initial Data Collection and Processing
Copies of the EMERG-AF study protocol (including definitions and 
codes) were provided to all collaborating researchers, who were 
trained by the lead investigator in data recording. The informa-
tion was collected in a centralized electronic file after interviewing 
patients or their relatives and later checked and completed by chart 
review. The study’s scientific committee made no therapeutic recom-
mendations and provided no specific instructions about AF and its 
management during the data collection.
The following information was included on the initial data collec-
tion sheet: demographic data, comorbidities, disability (according to 
the Katz scale),15 type of AF, duration of the current AF episode, risk 




-VASc score),16 bleeding risk (accord-
ing to the HAS-BLED score [Hypertension, Abnormal Renal and 
Liver Function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or 
Alcohol]),17 current stroke prophylaxis (anticoagulation, antiplatelet 
therapy, or both), symptoms that caused ED consultation, clinical 
presentation, and ED evaluation, patients’ final outcome (discharge, 
admission, or death), and stroke prophylaxis prescribed in the ED.
If anticoagulation was not prescribed, the treating physician was 
asked to select a reason from a set of multiple-choice possibilities. We 
included the most frequent causes of a lack of anticoagulant prescrip-
tion, as stated in daily practice studies,2,3,10 with the aim of capturing 
the main reasons for this behavior (Table I in the online-only Data 
Supplement).
Major bleeding was defined as potential risk of death because of 
bleed location (ie, intracranial, intraspinal, pericardial), potential risk 
of severe sequelae (intraocular, intramuscular with compartment syn-
drome), or required admission, surgery, or blood transfusion.18
Follow-Up
Follow-up in both groups included a phone call and a review of each 
patient’s electronic medical record at 1 year (±4 weeks) postinclusion 
to address long-term outcomes. The follow-up analysis included the 
following variables: bleeding events, systemic embolism and stroke 
events, stroke prophylaxis at the time of follow-up, and mortality 
(date and cause of death). If bleeding or a stroke or systemic embo-
lism had occurred, type of bleeding (minor or major) or type of com-
plication, respectively, were recorded along with date of presentation, 
location, and outcome.
The study’s scientific committee independently reviewed all data-
sheets to detect inconsistencies. As needed, a query was made to 
the principal investigator at the corresponding center to resolve any 
questions.
Outcome Measures
As the main objective of the present article was patient safety at 1 year 
post-discharge, incidence of major bleeding was the primary outcome. 
Mortality and stroke/systemic embolism were secondary outcomes.
Statistical Analysis
All analysis was performed with SPSS 20.0 and SAS statistical soft-
ware packages, accepting a risk threshold for a 2-sided Type I error 
of 5%. Differences in the profiles of patients with or without antico-
agulation treatment at discharge were assessed by Fisher exact test or 
t test for independent groups for quantitative or qualitative variables, 
respectively.
Univariate logistic regression models were built to assess the risk 
of major bleeding or death. The models estimated the hazard ratio 
(HR) and 95% CI using the most relevant clinical and demographic 
factors: age, sex, hypertension, diabetes mellitus, renal failure, acute 





-VASc, HAS-BLED, concomitant antiplatelet 
treatment, previous major bleeding, and relationship between the rea-
son for ED consultation and AF (yes/no), and destination. Because 
the prescription of anticoagulant therapy was the main variable of 
interest, we conducted a number of multivariate analyses, adjusting 
by these factors to assess its relevance as a potential independent pre-
dictor for hemorrhagic events or death. All analyses were also per-
formed for patients without previous stroke prophylaxis treatment.
Results
Characteristics of Study Participants
During the study period, 1162 patients were included (mean 
age, 74.7 years [SD 11.2], 590 [50.8%] women). In 178 patients 
(15.3%), de novo AF diagnosis was made during the ED inclu-
sion visit. Comorbid conditions were common. The majority 
(88.1%) of the patients included were at high risk of stroke 




-VASc score. Demographic and clin-
ical characteristics of all patients and of patients without previ-
ous anticoagulation are listed in Table 1. Two patients (0.2%) 
died during the ED stay. After evaluation, 512 patients (44.0%) 
were admitted, and 648 patients (55.8%) were discharged home.
Main Results
Anticoagulation Prescription
At the time of the ED visit, 733 patients (63.1%) were taking 
anticoagulants. At ED discharge, 935 patients (80.5%), includ-
ing those diagnosed de novo, were receiving antithrombotic ther-
apy with anticoagulants (146 with concomitant antiplatelets). 
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Table 2 details ED anticoagulation prescription according to 
stroke risk. Considering both previous and de novo anticoagu-





VASc score (14.3%) did not receive anticoagulation therapy at 
discharge from the ED. The main reasons given by the treating 
physicians for not prescribing anticoagulation in these high-risk 
patients were high risk of bleeding (81 patients [48.8%]) and no 
indication for anticoagulation (56 patients [33.7%]).
Of the 935 patients anticoagulated at ED discharge, 
764 (81.7%) received vitamin K antagonists, 97 (10.4%) 
low-molecular-weight heparin, 73 (7.8%) direct oral anti-
coagulants, and 1 patient (0.1%) other anticoagulation. 
Prescriptions were de novo in 237 patients (55.2% of the 429 
not previously anticoagulated). At discharge, all participants 
were referred to another healthcare facility for follow-up and 
long-term monitoring.
Follow-Up
After 1 year, 58 patients (4.9%) were deceased, and 52 patients 
(4.4%) were lost to follow-up. The reasons for losses to follow-up 
Table 1.  Demographic and Clinical Characteristics of All Patients and Patients Without Previous Anticoagulation
Variable Total, n=1162, n (%)
Not Previously Anticoagulated
Total, n=429, n (%)





n (%) P Value
Age, mean (SD) 74.7±11.2 72.4±13.0 71.5±15.0 73.1±11.0 0.22
Sex (female) 590 (50.8) 204 (47.6) 95 (49.5) 109 (46.0) 0.47
Structural heart disease 585 (50.3) 129 (30.1) 56 (29.2) 73 (30.8) 0.71
Acute heart failure 406 (34.9) 87 (20.3) 33 (17.2) 54 (22.8) 0.18
Left ventricular dysfunction 209 (18) 41 (9.6) 17 (8.9) 24 (10.1) 0.65
Hypertension 868 (74.7) 286 (66.7) 113 (58.9) 173 (73.0) 0.002
Previous stroke 172 (14.8) 47 (11.0) 21 (11.0) 26 (11.0) 1.00
Previous systemic embolism 19 (1.6) 1 (0.2) 1 (0.5) 0 (0.0) 0.26
Diabetes mellitus 316 (27.2) 92 (21.5) 34 (17.8) 58 (22.5) 0.09






  0 49 (4.2) 39 (9.0) 28 (14.6) 11 (4.6)
<0.001  1 89 (7.7) 55 (12.8) 31 (16.1) 24 (10.1)
  ≥2 1024 (88.1) 335 (78.1) 133 (69.3) 202 (85.2)
HAS-BLED
  <3 568 (48.9) 242 (56.5) 99 (51.8) 143 (60.3)
0.08
  ≥3 594 (51.1) 187 (43.6) 93 (48.4) 94 (39.7)
Disability 126 (10.8) 44 (10.0) 24 (12.0) 20 (8.4) 0.17
  Total 8 (0.7) 3 (0.7) 1 (0.5) 2 (0.8) 0.44
Types of AF
  First episode 178 (15.3) 164 (38.1) 49 (25.1) 115 (48.5)
<0.001
  Paroxysmal 312 (26.9) 154 (36.0) 81 (42.4) 73 (30.8)
  Persistent 131 (11.3) 44 (10.3) 15 (7.8) 29 (12.2)
  Permanent 541 (46.6) 67 (15.6) 47 (24.6) 20 (8.4)
Main complaint
  Related to AF* 681 (58.6) 318 (74.1) 111 (57.8) 207 (87.3)
<0.001
  Other 481 (41.4) 111 (25.9) 81 (42.2) 30 (12.7)
Duration of episode
  <48 h 210 (18.1) 141 (32.7) 73 (37.7) 68 (28.7)
0.010  >48 h 539 (46.4) 101 (23.6) 51 (26.7) 50 (21.1)
  Unknown 413 (35.5) 187 (43.7) 68 (35.6) 119 (50.2)
AF indicates atrial fibrillation.
*Related to AF or its treatment.
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were change of address or other factors making contact impossi-
ble (49 patients) and decision to withdraw (3 patients). One-year 
follow-up was completed by 956 patients (94.6% of survivors 
and 82.3% of all participants). At the end of the year, 699 
(73.1%) patients were taking anticoagulants; the great major-
ity of them (670 patients, 95.8%) received de novo or contin-
ued anticoagulant treatment at ED discharge. Anticoagulation 
persisted in 81.2% of the patients anticoagulated de novo who 
survived and completed follow-up. The 29 patients prescribed 
an anticoagulant during follow-up constituted 12.8% of the 227 
patients discharged without anticoagulation.
Primary Outcome: Safety
At the end of 1 year, 184 bleeding events had occurred in 150 
patients (12.9%), including 55 (29.8%) major bleeding epi-
sodes that occurred in 48 patients (4.1%), with 6 fatalities. 
The main bleeding sites were gastrointestinal (23.9%), oto-
rhynolaryngologic (22.7%), and urogenital (14.1%). Twelve 
patients had intracranial hemorrhage (6.5% of all bleeding 
events).
Anticoagulant treatment was not related to major bleeding 
(HR, 1.376; 95% CI, 0.581–3.260; Figure 1A). These results 
were similar when only patients who were not receiving anti-
coagulation before the index visit were taken into account 
(HR, 0.976; 95% CI, 0.294–3.236; Figure 1B), even when 
adjusted for possible confounders: final outcome in the first 
visit (discharge versus admission), antiplatelet treatment, or 
other relevant clinical or sociodemographic characteristics 
(Table 3). A separate analysis of discharged, not previously 
anticoagulated patients also found no significant relationship 
between starting anticoagulant treatment and major bleeding 
(HR, 2.597; 95% CI, 0.270–24.966).
Secondary Outcomes
Mortality: During the 1-year follow-up period, 151 patients 
(12.8%) died, 62 (41.6%) of them because of cardiovas-
cular causes. Anticoagulant treatment was associated with 
decreased mortality (HR, 0.505; 95% CI, 0.357–0.715; 
Figure 2A). This association also persisted when only patients 
who were not receiving anticoagulation before the index visit 
were taken into account (HR, 0.398; 95% CI, 0.231–0.686; 
Figure 2B), even when adjusted for the final outcome in the 
first visit (discharge versus admission), antiplatelet treatment, 
or any relevant clinical or sociodemographic characteristic 
(Table 4). When a separate analysis of the 257 discharged, 
not previously anticoagulated patients was performed, anti-
coagulated patients (n=137) had lower mortality than those 
discharged without anticoagulation (n=120) but the difference 
(5.8% versus 9.1% mortality, respectively) was nonsignificant 
(HR, 0.668; 95% CI, 0.264–1.694).
Stroke and systemic embolism: Thromboembolic complica-
tions were present in 31 patients (2.7%): 13 strokes, 8 tran-
sient ischemic attacks, and 13 systemic embolisms. Four of 
these patients died, and 15 were left with sequelae.
Anticoagulation was not associated with the presence of 
stroke events in the univariate analysis (HR, 0.929; 95% CI, 
0.381–2.264). When only patients not previously anticoagu-
lated were considered, those who received anticoagulants in 
the ED visit tended to have a lower incidence of embolic 
events, although this was not significant (2.1% versus 3.2%; 
HR, 0.614; 95% CI, 0.187–2.011), even when adjusted for 
final outcome, antiplatelet treatment, or any relevant clinical 
or sociodemographic characteristic (Table II in the online-
only Data Supplement). A separate analysis of discharged, 
not previously anticoagulated patients also found a nonsignifi-
cantly lower incidence of embolic complications (1.4% versus 
2.5%; HR, 0.556; 95% CI, 0.093–3.330).
Limitations
Participation in an investigative study may have had an 
impact on the clinicians. To minimize this limitation, risk 
stratification scores were not made available in the electronic 
record. The large number of researchers involved could have 
generated variability in interpreting the questions on the 
data collection sheet. To avoid this bias, multiple-choice 
responses were specified. In addition, verbal information 
obtained from patients at 1-year follow-up could have been 
affected by recall bias. However, all serious complications 
would likely have been attended in a hospital and reflected in 
the official records reviewed to ensure accuracy of outcome 
information.
The EMERG-AF study was not designed to compare differ-
ences in effectiveness between stroke prophylaxis prescribed 
in EDs and that prescribed in other clinical settings. No such 
conclusions should be inferred from the study results.
Table 2. Anticoagulation at Discharge From the Emergency Department According to Stroke Risk, Previous Treatment, 





-VASc Previous Anticoagulation, n (%) Anticoagulation at Discharge From ED, n (%) Admitted, n (%) Discharged, n (%)
<2, n=138 Yes 44 (31.9) Yes 42 (95.5) 16 (38.1) 26 (61.9)
No 2 (4.5) 0 (0.0) 2 (100)
No 94 (68.1) Yes 35/94 (37.2)* 8 (22.9) 27 (77.1)
No 59 (62.8) 6 (10.2) 53 (89.8)
≥2, n=1024 Yes 688 (67.3) Yes 656 (95.3) 298 (45.4) 358 (54.6)
No 33 (4.7) 27 (84.4) 5 (15.6)
No 334 (32.7) Yes 202 (60.5) 92 (45.5) 110 (54.5)
No 133 (39.5) 65 (49.2) 67 (50.8)
ED indicates emergency department.
*Eighteen of these patients were anticoagulated for subsequent elective cardioversion after ED discharge.
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Finally, our results can be generalized to the Spanish 
National Health System and other closely related systems. 
Further studies are needed to confirm the external validity of 
these results.
Discussion
The EMERG-AF is the first study to date to prospectively 
analyze the long-term effects of the ED physician’s contribu-
tion to stroke prophylaxis in AF patients, both in prescribing 
anticoagulation de novo in high-risk patients and in reinforc-
ing the therapeutic message and encouraging long-term adher-
ence in those patients already taking anticoagulants. In this 
representative sample of EDs in Spain, the clinical features 
and stroke risk of the patients included were comparable to 
those in the global AF population, especially those attended in 
EDs, as described in the largest studies to date.2,3,19 Therefore, 
the results obtained may be widely applicable to ED daily 
practice.
Figure 1. Kaplan–Meier curves showing time to first major bleeding according to anticoagulant treatment. A, All patients; B, patients who 
were not receiving oral anticoagulation when they arrived to the emergency department.
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This study yielded 3 main conclusions. First, prescrib-
ing anticoagulants in the ED to AF patients at a high risk of 
stroke is not only feasible but also beneficial in the long term, 
with a favorable safety profile. Anticoagulation was pre-
scribed by the ED physicians without requiring other medical 
assessments, and instructions for therapy and referral to other 
healthcare settings were provided exclusively by ED physi-
cians and nurses. In addition, the prescription followed cur-
rent guidelines in the vast majority of cases. Nevertheless, and 
despite the high level of anticoagulation found in our series, 
almost 15% of eligible patients were not taking anticoagu-
lants at discharge. This highlights the need for an additional 
effort to provide this prescription to all high-risk patients.
Second, the safety profile of anticoagulation prescribed 
in EDs, following the guidelines’ recommendations and 
providing systematic referral for follow-up at discharge, is 
at least as safe in the long term as are prescriptions made 
in other healthcare settings.6–9,20 After adjusting for clinical 
and sociodemographic variables, the major bleeding rate in 
patients anticoagulated de novo at the ED was similar to that 
in nonanticoagulated patients. Moreover, these good results 
reflect not only an adequate indication for anticoagulation, 
but also appropriate referrals to INR monitoring. Together 
with the finding that the majority of patients in whom anti-
coagulation was prescribed de novo at the ED were adhering 
to treatment at 1-year follow-up, these results strongly sup-
port an assertion that accurate prescription of anticoagulants 
is feasible in the daily ED practice and suggest that deci-
sions made in the ED influence longitudinal care, as recently 
reported by Atzema et al.21
The third main result of our study was that the good patient 
safety outcomes were not achieved at the expense of effective-
ness. Although there were no significant differences in the benefits 
of anticoagulant prescription in the ED with respect to embolic 
events, likely because of the overall paucity of such events, the 
impact on mortality was overwhelmingly positive. Mortality 
decreased overall and in patients without previous anticoagula-
tion, even after adjusting for all confounding variables. When a 
separate analysis was performed on discharged, not previously 
anticoagulated patients, although the mortality was lower in anti-
coagulated patients, the difference was not significant. The lack 
of significance in this subpopulation is likely because of the lower 
global mortality that would be expected in discharged patients. 
Although the study was not sufficiently powered for the analy-
sis of subpopulations, this does not lessen the implications of 
the results because the aim was to analyze the long-term effects 
of the ED physician’s contribution to overall stroke prophylaxis 
in AF patients. Moreover, although the management of patients 
with AF is guided by a common protocol and is highly consis-
tent among EDs in Spain, the management of admissions var-
ies greatly between the participating hospitals; thus, many of the 
included patients were admitted to an Observation Unit or Short 
Stay Unit, in most cases headed by a physician from the ED staff.
It can be argued that these long-term good results could 
also be attributed to patient management by other healthcare 
specialists after ED discharge. We certainly agree with this 
because the objectives of the EMERG-AF study were to ana-
lyze the contribution of ED physicians to the multidisciplinary 
team approach to stroke prophylaxis in patients with AF,6 not 
to assess in isolation the benefits of prescribing anticoagulants 







Multivariate (Anticoagulation at 
Discharge, Adjusted by Each Variable)
HR 95% CI HR 95% CI
Anticoagulation at discharge 231 (55.26) 6 (54.55) 0.976 0.294–3.236 Nonestimable
Destination (discharged home) 253 (60.53) 4 (36.36) 0.369 0.107–1.277 0.868 0.261–2.882
Age ≥75 y 203 (48.56) 8 (72.73) 2.915 0.769–11.050 0.908 0.275–2.996
Sex (female) 198 (47.37) 6 (54.55) 1.286 0.389–4.244 0.997 0.298–3.339
Hypertension 280 (66.99) 6 (54.55) 0.701 0.210–2.343 1.013 0.305–3.368
Diabetes mellitus 89 (21.29) 3 (27.27) 1.554 0.402–6.009 0.936 0.280–3.132
Renal failure 50 (11.96) 5 (45.45) 6.020 1.794–20.197 0.814 0.245–2.704
Acute heart failure 84 (20.10) 3 (27.27) 1.462 0.385–5.553 0.913 0.270–3.082
Structural heart disease 121 (28.95) 8 (72.73) 6.055 1.585–23.131 0.872 0.265–2.874
Cerebrovascular disease 44 (10.53) 3 (27.27) 2.703 0.694–10.520 0.899 0.273–2.960
Disability 42 (10.05) 2 (18.18) 2.580 0.547–12.157 1.028 0.309–3.424
Consultation related to AF 314 (75.15) 4 (36.36) 7.231 1.869–27.973 2.078 0.592–7.293





-VASc score of ≥2 326 (77.99) 9 (81.82) 1.432 0.308–6.647 0.903 0.264–3.086
HAS-BLED score of ≥3 179 (42.82) 8 (72.73) 3.931 1.041–14.841 0.939 0.285–3.086
Concomitant antiplatelet treatment 179 (42.82) 4 (36.36) 0.723 0.209–2.506 0.822 0.220–3.069
Previous major bleeding 67 (16.03) 3 (27.27) 2.513 0.649–9.729 1.103 0.327–3.724
Definitions detailed in the Statistical Analysis. AF indicates atrial fibrillation; CI, confidence interval; and HR, hazard ratio.
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in the acute setting. Indeed, as a general rule and as one of the 
pillars of starting anticoagulation, all AF patients discharged 
from EDs in our setting are referred to another level of health 
care (internal medicine, cardiology, neurology, geriatrics, and 
primary care) for follow-up and to specialized clinics or pri-
mary care to monitor anticoagulation and reinforce patient 
education. Thus, our results are an accurate reflection of 
the potential benefits of a coordinated and multidisciplinary 
strategy of stroke prophylaxis involving ED physicians and 
nurses, and specifically highlight the potential ED contribu-
tion to maximize appropriate prophylaxis in these patients.22–24
Conclusions
Prescription in the ED of anticoagulation in AF patients at 
a high risk of stroke is not only feasible but also beneficial 
in the long term to decrease mortality. Therefore, the active 
Figure 2. Kaplan–Meier curves showing mortality according to anticoagulant treatment. A, All patients; B, patients who were not receiving 
oral anticoagulation when they arrived to the emergency department.
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involvement of ED physicians could help to improve the 
global results of stroke prophylaxis in AF and thus help to 
improve the prognosis and quality of life of this increasing 
population of patients attended in the acute setting.
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